CiiTA Managing Partner: Risk to Manufacturers Letter to the Editor

The P&T (Pharmacy and Therapeutics) Community online journal has published a response by CiiTA’s Managing Partner, Jason Hardaway, to their October 2015 report by Stephen Barlas about Congress’s 340B Program omnibus guidance issued by the Health Resources and Services Administration (HRSA). Mr. Hardaway’s article, titled 340B Program Puts Manufacturers At Risk of Duplicate Drug Discounts, addresses the material and financial risk of duplicate discounts on drug manufacturers. To read his response, please follow the link above.